Pfizer said the green light makes Hympavzi the first once-weekly subcutaneous treatment in the European Union for people with severe hemophilia B and the first to be administered via a pre-filled pen ...

Drug major Pfizer Inc. (PFE) announced Wednesday that the European Commission or EC has granted marketing authorization for HYMPAVZI ...

A federal judge on Tuesday rejected Pfizer's bid to recoup about $75.2 million left over from a U.S. Securities and Exchange ...

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control ...

Pfizer PFE-1.80%decrease; red down pointing triangle punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results. The pharmaceutical company raised its ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - The Pfizer logo is displayed at the company’s headquarters, Friday, Feb. 5, 2021, in New York. (AP ...

Pfizer Inc.’s stock was unable to hold its early gains Tuesday and fell 2.4% after the company blew past estimates for the third quarter and raised its full-year guidance. The New York-based ...

Pfizer’s respiratory syncytial virus (RSV) pipeline appears to have run dry of candidates following the cessation of work on both an oral medicine and an RSV-flu combo vaccine in quick succession.

Pfizer, facing down a contentious challenge from an activist investor, reported earnings for the third quarter Tuesday that handily beat Wall Street forecasts and led it to boost revenue guidance for ...

NEW YORK (Reuters) - Pfizer's quarterly financial report on Tuesday comes at a critical moment for the U.S. drugmaker and its CEO, as activist hedge fund Starboard Value ramps up the pressure to ...